DW Healthcare Partners Announces Sale of LKC Technologies to AMETEK, Inc.

DW Healthcare Partners Announces Sale of LKC Technologies to AMETEK, Inc.

DW Healthcare Partners ("DWHP"), a healthcare-focused private equity firm, today announces the sale of LKC Technologies to AMETEK, Inc. (NYSE: AME).

As leaders in the world of visual electrophysiology, LKC Technologies, a portfolio company of DW Healthcare Partners' Founders Fund, is dedicated to preserving sight by expanding access to objective functional retinal assessments. For over 35 years, LKC has pioneered innovations in diagnostic technology, transforming complex visual electrophysiology into intuitive, accessible solutions for clinicians and researchers worldwide.

Building on decades of industry leadership, the company's handheld, non-invasive electroretinography (ERG) device, the RETeval, delivers reliable, objective data that supports the diagnosis and management of retinal and optic nerve diseases. Anchored by a mission to improve patient outcomes, LKC empowers eye care professionals with innovative tools and quality customer service to advance clinical care and accelerate research. "We would like to thank the team at DWHP for their tremendous support over the last three years." stated Dina Dubey, CEO of LKC Technologies. "They have been wonderful partners and have made significant contributions to the incredible growth and success of the company."

"LKC Technologies represents exactly the kind of opportunity we look for—a company with a deeply rooted mission and a product that fundamentally changes patient outcomes," said Gabe Becher, Managing Director at DW Healthcare Partners. "Over the course of our partnership, we worked closely with the exceptional team at LKC to scale their operations and raise awareness of functional retinal testing in detecting sight-threatening diseases early. We are incredibly proud of what the company achieved and look forward to watching LKC continue to flourish."

William Blair served as exclusive financial advisor to LKC Technologies.

About DW Healthcare Partners

DW Healthcare Partners is a private equity firm focused exclusively on the healthcare industry. The firm manages six funds with over $2.7 billion in assets under management, as of December 31, 2025. DW Healthcare Partners is led by seasoned executives with more than 155 years of combined healthcare industry and investing experience. The firm provides capital, strategic guidance, and acquisition support to help mid-stage companies grow and scale. For more information, please visit: dwhp.com

Media Contact: acc@dwhp.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/dw-healthcare-partners-announces-sale-of-lkc-technologies-to-ametek-inc-302677140.html

SOURCE DW Healthcare Partners

News Provided by PR Newswire via QuoteMedia

AME
The Conversation (0)
MAYFAIR GOLD APPOINTS CHIEF PROJECTS OFFICER AND SENIOR VICE PRESIDENT, SUSTAINABILITY AS FENN-GIB ADVANCES TOWARD DEVELOPMENT

MAYFAIR GOLD APPOINTS CHIEF PROJECTS OFFICER AND SENIOR VICE PRESIDENT, SUSTAINABILITY AS FENN-GIB ADVANCES TOWARD DEVELOPMENT

Mayfair Gold Corp. ("Mayfair", "Mayfair Gold", or the "Company") (TSXV: MFG,OTC:MFGCF) (NYSE American: MINE) is pleased to announce the appointments of Desmond "Des" Tranquilla as Chief Projects Officer and Ruben Wallin as Senior Vice President, Sustainability. The appointments deepen the... Keep Reading...
Preparatory Infrastructure Work for Pilot Plant and Mining on the HMS TitanBeach Titanium Project in Morocco Begins. Company Options Issued

Preparatory Infrastructure Work for Pilot Plant and Mining on the HMS TitanBeach Titanium Project in Morocco Begins. Company Options Issued

(TheNewswire) TitanBeach Mining License and an established full, non-dilutive 32% carried interest for NSM Capital in the project's development and the signing of a State-Owed Enterprise Framework Agreement with new SPV, Shan Tang Mining Muskoka, Ontario TheNewswire - August 20th, 2026... Keep Reading...
American Uranium

Large-Scale Aquifer Testing Commences at Lo Herma as ProjectAdvances Toward ISR Development

Large scale hydrogeological testing is now underway at Mine Unit 1 following AMU's recent 9.96Mlb resource update, supporting permitting activities and the Company's targeted Q4 2026 Scoping Study.American Uranium Limited (ASX:AMU, OTC:AMUIF) (American Uranium, AMU or the Company) is pleased to... Keep Reading...
Jaguar Uranium Reports Final Copper Assay Results Including up to 8.54% Copper, Potential 4-km Trend Identified from Huemul Uranium-Copper-Vanadium Project

Jaguar Uranium Reports Final Copper Assay Results Including up to 8.54% Copper, Potential 4-km Trend Identified from Huemul Uranium-Copper-Vanadium Project

Channel and rock chip samples from areas of visible uranium-copper-vanadium mineralization observed at surface returned final assay results for copper (up to 8.54%), uranium (up to 2.27%), silver (up to 708 g/t) and vanadium (up to 1.27%)1. Sampling of strike extensions along the Uryco/Rosa and... Keep Reading...
Jaguar Uranium Reports Final Copper Assay Results Including up to 8.54% Copper, Potential 4-km Trend Identified from Huemul Uranium-Copper-Vanadium Project

Jaguar Uranium Reports Final Copper Assay Results Including up to 8.54% Copper, Potential 4-km Trend Identified from Huemul Uranium-Copper-Vanadium Project

Channel and rock chip samples from areas of visible uranium-copper-vanadium mineralization observed at surface returned final assay results for copper (up to 8.54%), uranium (up to 2.27%), silver (up to 708 g/t) and vanadium (up to 1.27%)1. Sampling of strike extensions along the Uryco/Rosa and... Keep Reading...

Interactive Chart

Latest Press Releases

Related News